The effect of airway pressure release ventilation on respiration and circulation in post-operative heart surgery patients

ISRCTN ISRCTN92666776
DOI https://doi.org/10.1186/ISRCTN92666776
Secondary identifying numbers 20181225-6
Submission date
01/02/2020
Registration date
10/02/2020
Last edited
28/03/2023
Recruitment status
No longer recruiting
Overall study status
Completed
Condition category
Respiratory
Prospectively registered
Protocol
Statistical analysis plan
Results
Individual participant data

Plain English summary of protocol

Background and study aims
Postoperative lung (pulmonary) complications and heart (cardiovascular) complications are major causes of morbidity, mortality and resource utilization in cardiac surgery patients. Patients undergoing cardiopulmonary bypass (CPB) frequently experience hypoxemia and pulmonary complications after surgery and may develop acute respiratory distress syndrome. In addition, improper postoperative ventilator settings are associated with an increased risk for lung infection, a longer duration of intubation and a longer hospital stay.

Airway pressure release ventilation (APRV) is a lung protective strategy that has been proposed to treat refractory hypoxemic respiratory failure while preventing ventilator-induced lung injury . However, APRV introduces a higher mean airway pressure (Pmean) compared to conventional ventilation mode, which may increase intrathoracic pressure, and subsequently right atrial pressure. Hence, APRV might lead to a decrease in systemic venous return compared to conventional mechanical ventilation. A randomized controlled trial was designed to compare APRV with conventional PCV.

Who can participate?
Patients aged over 18 years who receive cardiothoracic surgery and need invasive mechanical ventilation after admission to the ICU.

What does the study involve?
Patients are randomly divided into routine ventilation group (PCV group) and APRV group and treated accordingly.

What are the possible benefits and risks of participating?
The use of APRV mode during postoperative respiratory support may promote pulmonary retention after general anesthesia, reduce postoperative complications, and shorten mechanical ventilation and ICU stay.And during the study, we continued to monitor the patient's ventilation indicators and vital signs. The electrical impedance imaging test used in the study was non-invasive in vitro, requiring only chest straps placed before and after the roll, without frequent movement. Therefore, this study is relatively safe.

Where is the study run from?
Sir Run Run Shaw Hospital Affiliated to Medical College of Zhejiang University (China)

When is the study starting and how long is it expected to run for?
December 2018 to December 2021

Who is funding the study?
Sir Run Run Shaw Hospital Affiliated to Medical College of Zhejiang University (China)

Who is the main contact?
Mrs Jie Ding
2233702918@qq.com

Contact information

Mrs Jie Ding
Scientific

3 Qingchun East Road
Jianggan District
Hangzhou
310016
China

Phone +86 18268113280
Email 2233702918@qq.com

Study information

Study designInterventional randomized controlled trial
Primary study designInterventional
Secondary study designRandomised controlled trial
Study setting(s)Hospital
Study typeTreatment
Participant information sheet Not available in web format, please use the contact details below to request a patient information sheet
Scientific titleThe effect of airway pressure release ventilation (APRV) on the incidence of postoperative pulmonary complications in patients with cardiothoracic surgery
Study objectivesThe use of APRV mode in post-operative cardiac surgery patients can promote pulmonary retention after general anesthesia, reduce postoperative complications and shorten mechanical ventilation and ICU stay.
Ethics approval(s)Approved 25/12/2018, Ethics committee of Sir Run Run Shaw Hospital of Zhejiang University (3 Qingchun East Road, Jianggan District, Hangzhou, 310016, China; +86 571 8600681; 594961420@qq.com), ref: 20181225-6
Health condition(s) or problem(s) studiedPostoperative pulmonary complications and cardiovascular complications
InterventionPatients who receive cardiothoracic surgery and need invasive mechanical ventilation after admission to the ICU are randomly divided into routine ventilation group (PCV group) and APRV group. The random scheme is generated by referring to the random comparison table without any restriction, intervention or adjustment in advance or in the process of implementation.

All patients are supported by Evita4 ventilator, and the initial parameters of a ventilator in the PCV group are set as follows: respiratory frequency 12 times/min, tidal volume 6-8ml/ ideal kg body weight, inhalation oxygen concentration and positive end-expiratory pressure (PEEP) are set according to the needs of patients.
The initial respiratory rate, tidal volume, and inhaled oxygen concentration of the APRV group are set the same as that of the conventional ventilator group, with the low pressure set to 0, and the low pressure time (Tlow) is set at the time required to reduce the flow rate at pressure release to 50%-75% of the peak flow rate. The distribution of functional residual gas and tidal gas is measured by EIT equipment at the time of enrollment, 30min and 1h after enrollment. Vital signs and respiratory physiological indicators are also recorded as well as the incidence of ventilator-associated pneumonia, atelectasis, mechanical ventilation duration, length of ICU stay, and final prognosis.
Intervention typeDevice
Pharmaceutical study type(s)
PhaseNot Applicable
Drug / device / biological / vaccine name(s)Evita4 ventilator
Primary outcome measureElectrical impedance imaging (EIT) was used to determine the difference in pulmonary gas distribution in patients undergoing cardiothoracic surgery before and after admission to the ICU after APRV
Secondary outcome measuresFrom patient records:
1. Incidence of ventilator-associated pneumonia
2. Incidence of atelectasis
3. Duration of mechanical ventilation
4. Length of ICU stay
5. Final outcome (death/survival)
Overall study start date25/12/2018
Completion date31/12/2021

Eligibility

Participant type(s)Patient
Age groupAdult
Lower age limit18 Years
SexBoth
Target number of participantsPCV group: 30 and APRV group:30
Key inclusion criteria1. Age above 18
2.Received cardiothoracic surgery and needed invasive mechanical ventilation after admission to the ICU
Key exclusion criteria1. Chronic obstructive pulmonary disease
2. Asthma
3. Mechanical ventilation pre-operation
4. Mechanical device to maintain hemodynamics
Date of first enrolment26/12/2018
Date of final enrolment26/12/2021

Locations

Countries of recruitment

  • China

Study participating centre

Sir Run Run Shaw Hospital Affiliated to Medical College of Zhejiang University
3 Qingchun East Road
Jianggan District
Hangzhou
310016
China

Sponsor information

Sir Run Run Shaw Hospital
Hospital/treatment centre

3 Qingchun East Road
Jianggan District
Hangzhou
310016
China

Phone +86 (0)571 86006664
Email wangjing0919@srrsh.com
Website http://www.srrsh.com/html/main/gb2312/
ROR logo "ROR" https://ror.org/00ka6rp58

Funders

Funder type

Hospital/treatment centre

Sir Run Run Shaw Hospital Affiliated to Medical College of Zhejiang University

No information available

Results and Publications

Intention to publish date31/05/2022
Individual participant data (IPD) Intention to shareYes
IPD sharing plan summaryAvailable on request
Publication and dissemination planPlanned publication in a high-impact peer-reviewed journal.
IPD sharing planThe datasets generated during and/or analysed during the current study are available from the corresponding author on reasonable request beginning 9 months and ending 36 months following article publication.

Study outputs

Output type Details Date created Date added Peer reviewed? Patient-facing?
Results article 03/06/2021 28/03/2023 Yes No

Editorial Notes

28/03/2023: Publication reference added.
11/06/2020: The following changes were made to the trial record:
1. The recruitment end date was changed from 26/05/2020 to 26/12/2021.
2. The overall trial end date was changed from 20/06/2020 to 31/12/2021.
3. The intention to publish date was changed from 20/05/2021 to 31/05/2022.
10/02/2020: Trial’s existence confirmed by Ethics committee of Sir Run Run Shaw Hospital of Zhejiang University.